Austin Yeargan III1*, Bailey Montgomery2, Matt Murphy2, Katie Whitney3, Peter Millett3 and Thos Evans3
1The Regenerative Medicine Clinic, Wilmington, North Carolina, USA
2Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
3The Steadman Clinic, 181 West Meadow Drive, Vail, Colorado, USA
*Corresponding Author: Austin Yeargan III, The Regenerative Medicine Clinic, Wilmington, North Carolina, USA.
Received: March 11, 2020; Published: July 30, 2020
Osteoarthritis causes a heavy disease burden globally and treatments are continually evolving. We introduced an autologous cell therapy protocol in 2006 that has continued to demonstrate promise clinically and on advanced imaging studies. In this report, we detail applicable scientific concepts, our surgical technique and present a case report for illustration.
Keywords: Osteoarthritis; Subchondral Bone; Nanoplastytm and Mechanical Axis Deviation Protocol (NAMAD®)
Citation: Austin Yeargan III., et al. “Could the Yeargan Autologous Subchondral Nanoplastytm and Mechanical Axis Deviation Protocol (NAMAD®) Halt Molecular Progression and Reverse the Clinical Symptoms of Knee Osteoarthritis? Clinical and Scientific Concepts with Case Presentation Including T2 Wetmap Cartigram® sequencing". Acta Scientific Orthopaedics 3.8 (2020): 40-50.
Copyright: © 2020 Austin Yeargan III., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.